This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wise, R.
Right arrow Articles by Hartman, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wise, R.
Right arrow Articles by Hartman, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1999, p. 1508-1510, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Pharmacokinetics and Inflammatory-Fluid Penetration of Moxifloxacin following Oral or Intravenous Administration

Richard Wise,* Jennifer M. Andrews, Gill Marshall, and Giles Hartman

Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom

Received 6 November 1998/Returned for modification 24 February 1999/Accepted 26 March 1999

A single 400-mg oral or intravenous (i.v.) dose of moxifloxacin was given to each of eight healthy male volunteers, and 6 weeks later the dose was administered by the other route. The concentrations of the drug in plasma, cantharidin-induced inflammatory fluid, and urine were measured over the subsequent 24 h. The mean maximum concentrations observed in plasma were 4.98 µg/ml after oral dosing and 5.09 µg/ml after i.v. dosing. The mean maximum concentrations attained in the inflammatory fluid were 2.62 and 3.23 µg/ml, respectively. The mean elimination half-lives from plasma were 8.32 and 8.17 h, respectively. The overall penetration into the inflammatory fluid was 103.4 and 104.2%. Over 24 h 15% of the drug was recovered in the urine when administered by either route.

* Corresponding author. Mailing address: Department of Medical Microbiology, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, United Kingdom. Phone: 44 121 507 4255. Fax: 44 121 551 7763. E-mail: R.Wise{at}bham.ac.uk.

Antimicrobial Agents and Chemotherapy, June 1999, p. 1508-1510, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ober, M. C., Hoppe-Tichy, T., Koninger, J., Schunter, O., Sonntag, H.-G., Weigand, M. A., Encke, J., Gutt, C., Swoboda, S. (2009). Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. J Antimicrob Chemother 64: 1091-1095 [Abstract] [Full Text]  
  • Skalioti, C., Tsaganos, T., Stamatiadis, D., Giamarellos-Bourboulis, E. J., Boletis, J., Kanellakopoulou, K. (2009). PHARMACOKINETICS OF MOXIFLOXACIN IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS. pdi 29: 575-579 [Abstract] [Full Text]  
  • Landersdorfer, C. B., Kinzig, M., Hennig, F. F., Bulitta, J. B., Holzgrabe, U., Drusano, G. L., Sorgel, F., Gusinde, J. (2009). Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation. Antimicrob. Agents Chemother. 53: 2074-2081 [Abstract] [Full Text]  
  • Brillault, J., De Castro, W. V., Harnois, T., Kitzis, A., Olivier, J.-C., Couet, W. (2009). P-Glycoprotein-Mediated Transport of Moxifloxacin in a Calu-3 Lung Epithelial Cell Model. Antimicrob. Agents Chemother. 53: 1457-1462 [Abstract] [Full Text]  
  • Grayo, S., Lott-Desroches, M.-C., Dussurget, O., Respaud, R., Fontanet, A., Join-Lambert, O., Singlas, E., Le Monnier, A. (2008). Rapid Eradication of Listeria monocytogenes by Moxifloxacin in a Murine Model of Central Nervous System Listeriosis. Antimicrob. Agents Chemother. 52: 3210-3215 [Abstract] [Full Text]  
  • Almeida, D., Nuermberger, E., Tyagi, S., Bishai, W. R., Grosset, J. (2007). In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 51: 4261-4266 [Abstract] [Full Text]  
  • Grossi, O., Caillon, J., Arvieux, C., Jacqueline, C., Bugnon, D., Potel, G., Hamel, A. (2007). In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model. Antimicrob. Agents Chemother. 51: 3401-3403 [Abstract] [Full Text]  
  • Skiadas, I., Pefanis, A., Papalois, A., Kyroudi, A., Triantafyllidi, H., Tsaganos, T., Giamarellou, H. (2007). Dexamethasone as Adjuvant Therapy to Moxifloxacin Attenuates Valve Destruction in Experimental Aortic Valve Endocarditis Due to Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2848-2854 [Abstract] [Full Text]  
  • Wacke, R., Forster, S., Adam, U., Mundkowski, R. G., Klar, E., Hopt, U. T., Drewelow, B. (2006). Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 58: 994-999 [Abstract] [Full Text]  
  • Malincarne, L., Ghebregzabher, M., Moretti, M. V., Egidi, A. M., Canovari, B., Tavolieri, G., Francisci, D., Cerulli, G., Baldelli, F. (2006). Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 57: 950-954 [Abstract] [Full Text]  
  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
  • Rosenthal, I. M., Williams, K., Tyagi, S., Vernon, A. A., Peloquin, C. A., Bishai, W. R., Grosset, J. H., Nuermberger, E. L. (2005). Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 172: 1457-1462 [Abstract] [Full Text]  
  • Veziris, N., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V. (2005). Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice. Antimicrob. Agents Chemother. 49: 4015-4019 [Abstract] [Full Text]  
  • Fuhrmann, V., Schenk, P., Jaeger, W., Ahmed, S., Thalhammer, F. (2004). Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 54: 780-784 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 421-426 [Abstract] [Full Text]  
  • Bronner, S., Jehl, F., Peter, J.-D., Ploy, M.-C., Renault, C., Arvis, P., Monteil, H., Prevost, G. (2003). Moxifloxacin Efficacy and Vitreous Penetration in a Rabbit Model of Staphylococcus aureus Endophthalmitis and Effect on Gene Expression of Leucotoxins and Virulence Regulator Factors. Antimicrob. Agents Chemother. 47: 1621-1629 [Abstract] [Full Text]  
  • Yoshimatsu, T., Nuermberger, E., Tyagi, S., Chaisson, R., Bishai, W., Grosset, J. (2002). Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis. Antimicrob. Agents Chemother. 46: 1875-1879 [Abstract] [Full Text]  
  • Baden, L. R., Horowitz, G., Jacoby, H., Eliopoulos, G. M. (2001). Quinolones and False-Positive Urine Screening for Opiates by Immunoassay Technology. JAMA 286: 3115-3119 [Abstract] [Full Text]  
  • Rodriguez-Cerrato, V., McCoig, C. C., Michelow, I. C., Ghaffar, F., Jafri, H. S., Hardy, R. D., Patel, C., Olsen, K., McCracken, G. H. Jr. (2001). Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis. Antimicrob. Agents Chemother. 45: 3092-3097 [Abstract] [Full Text]  
  • Lubasch, A., Keller, I., Borner, K., Koeppe, P., Lode, H. (2000). Comparative Pharmacokinetics of Ciprofloxacin, Gatifloxacin, Grepafloxacin, Levofloxacin, Trovafloxacin, and Moxifloxacin after Single Oral Administration in Healthy Volunteers. Antimicrob. Agents Chemother. 44: 2600-2603 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»